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Introduction: Mammalian target of rapamycin complex 1 
(mTORC1) is an evolutionary conserved multiprotein complex that 
functions as a key regulator of gene transcription, protein translation, 
and autophagy. No studies have assessed associations between func-
tional single nucleotide polymorphisms (SNPs) in mTORC1 genes 
and risk of esophageal squamous cell carcinoma (ESCC).
Methods: In a case–control study of 1126 ESCC patients and 1131 
cancer-free controls, we genotyped eight SNPs in mTORC1 (mTOR 
rs1883965 G>A and rs2536 T>C, mLST8 rs3160 C>T and rs26865 
G>A, RPTOR rs3751934 C>A, rs1062935 T>C, rs3751932 T>C 
and rs12602885 G>A) and assessed their associations with risk 
of ESCC.
Results: In the single-locus analyses, we found a significantly altered 
risk of ESCC associated with mTOR rs1883965 A variant genotypes 
(adjusted OR = 1.27 and 1.26; 95% confidence interval = 1.01–1.60 
and 1.01–1.58 for GA and GA/AA, respectively, compared with GG) 
but not with other SNPs. In the combined analysis of the eight SNPs, 
we found individuals with two or more unfavorable genotypes exhib-
ited an increased risk for ESCC (adjusted OR = 1.35; 95% confi-
dence interval = 1.20–1.62), compared with those with less than two 
unfavorable genotypes. Such a cumulative effect was dose-dependent 
(p
trend
 = 0.004). In the multiple dimension reduction analysis, mTOR 
rs1883965 was consistently suggested as the strongest individual 
factor for ESCC risk, and the model including all SNPs yielded the 
lowest prediction error of 17.66% for model validation.
Conclusions: These findings suggest that functional SNPs of 
mTORC1 genes may individually or collectively contribute to ESCC 
risk. Further validation of these findings is warranted.
Key Words: mTORC1, Genetic polymorphisms, Risk, Esophageal 
cancer, Gene–environment interaction.
(J Thorac Oncol. 2013;8: 788-795)
Esophageal cancer has a markedly high incidence in China, compared with other geographical areas in the world. It 
is estimated that approximately 482,300 new esophageal can-
cer cases occurred in 2008 worldwide, about half of which 
took place in China with 90% of esophageal squamous cell 
carcinoma (ESCC). Previously established environmental risk 
factors for ESCC include tobacco use, alcohol consumption, 
nutrition deficiencies, and diet.1 However, these environmen-
tal risk factors cannot readily explain overall cancer incidence, 
and thus hereditary factors must be involved in the etiology of 
ESCC. Indeed, genetic variants in a variety of candidate genes 
have been demonstrated to be associated with ESCC risk.2,3
Recently, mammalian target of rapamycin complex 
1 (mTORC1) has emerged as a key regulator of numerous 
essential cellular processes, including translation, transcription, 
and autophagy,4 and deregulation of this complex has been 
found to contribute to the development of cancers and the 
curative effect of some anticancer drugs on cancers, including 
ESCC.5–8 Furthermore, the mTOR pathway was found to 
be aberrantly activated in most ESCC tumors, supporting a 
role for the mTOR activation in the etiology of ESCC.9 The 
mTOR gene, also known as FRAP1, has been mapped to 
chromosome 1p36.2 and encodes a 300 kDa protein kinase, 
which emerges as a critical component of an ancient nutrient 
and energy effector pathway.10 The mTOR has two distinct 
evolutionarily conserved complexes termed mTORC1 and 
mTORC2. The former is sensitive, but the latter is resistant, to 
the selective inhibitor rapamycin.11 Besides mTOR, mTORC1 
contains regulatory-associated protein of mTOR (RPTOR) 
and mLST8 (also known as GBL), both of which have a 
protein association.11 The RPTOR and mLST8 genes have been 
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mapped to 17q25.3 and 16p13.3, respectively. The RPTOR 
forms a stoichiometric complex with mTOR and plays a role 
in nutrient-stimulated signaling to S6K1, maintenance of cell 
size and mTOR protein expression,5 whereas the mLST8 can 
bind to the kinase domain of mTOR and regulate the mTOR 
kinase activity.11
In light of the critical role of the mTORC1 pathway in 
maintaining proper cellular function, it is possible that some 
functional single nucleotide polymorphisms (SNPs) of genes 
involved in this pathway may have an effect on cancer risk. 
Because no published studies have investigated the role of 
SNPs of the mTORC1 genes in the etiology of ESCC, we 
genotyped some selected potential functional SNPs of the 
mTORC1 genes and investigated their associations with the 
risk of ESCC in a Chinese population.
MATERIALS AND METHODS
Study Subjects
The study included 1126 patients with ESCC and 1131 
cancer-free controls, who were all genetically unrelated ethnic 
Han Chinese from Eastern China. Patients recruited into this 
study were diagnosed with newly diagnosed and histopatho-
logically confirmed primary ESCC from Shanghai Cancer 
Center, Fudan University between March 2009 and September 
2011, with a response rate of 93%. Exclusion criteria included 
patients who had other cancers, primary tumors outside the 
esophagus, and tumors of an unknown origin. Cancer-free 
controls, frequency matched to the cases by age (±5 years) 
and sex, were recruited from the Taizhou Longitudinal Study 
at the same time period, as described previously,12 in which the 
response rate was approximately 90% among those who were 
approached for participation in the study. Having provided 
a written informed consent, each participant was person-
ally interviewed for the collection of demographic data and 
environmental exposure history, such as age, sex, ethnicity, 
body mass index (BMI), tobacco and alcohol consumption. 
At the end of the interview, each subject donated approxi-
mately 10-ml venous blood sample, of which 1 ml was used 
for genomic DNA extraction. This study was approved by 
the institutional review board of the Shanghai Cancer Center, 
Fudan University.
SNP Selection and Genotyping
We searched the National Center for Biotechnology 
Information dbSNP database (http://www.ncbi.nlm.nih.gov/) 
for common, potentially functional SNPs and SNPinfo (http://
snpinfo.niehs.nih.gov/) to identify the candidate SNPs based 
on the following four criteria: (1) located at the regulatory 
region of genes (i.e., exon, the 5′ near gene, 5′ untranslated 
regions [UTR], 3′UTR, 3′ near gene and splice sites); (2) the 
minor allele frequency (MAF) ≥ 5% in Chinese Han, Beijing 
descendants reported in HapMap; (3) affecting the microRNA 
binding sites activity or affecting transcription factor binding 
site activity in the putative promoter region or changing the 
amino acid in the exons; (4) not included in the SNP chips used 
in the published genome-wide association studies (GWAS) 
of ESCC. Only SNPs satisfied most of these criteria were 
finally selected. For the RPTOR gene, we initially identified 
eight SNPs (rs4890040, rs4890039, rs12602885, rs11658698, 
rs3751934, rs1062935, rs3751932, and rs1045626). However, 
because rs1045626 was in high LD with rs1062935 (r2 = 
0.976), we only chose rs1062935 in the 3′UTR region. In addi-
tion, we excluded three SNPs (rs11658698, rs4890040, and 
rs4890039) located in the 5′ near gene, because rs11658698 
was included in GWAS,13 whereas the other two SNPs were in 
high LD with rs11150863 (r2 = 0.975, 1.000 for rs4890040 and 
rs4890039, respectively), which is also included in GWAS.13 
As a result, we selected three SNPs in the 3′UTR of RPTOR 
(rs3751934 C>A, rs1062935 T>C, and rs3751932 T>C) 
and one SNP in the 5′UTR of RPTOR (rs12602885 G>A) 
for genotyping. For the mTOR gene, we initially identified 
three SNPs (rs1883965, rs2536, and rs12125777). Because 
rs12125777 was in complete LD with rs2536 (r2 = 1.000), we 
only chose rs2536 that was investigated in a previous study.14 
Finally, we included one SNP in the intron-1 region of mTOR 
(rs1883965 G>A), one SNP in the 3′UTR of mTOR (rs2536 
T>C) for genotyping. For the mLST8 gene, we initially con-
firmed three SNPs (rs26865, rs27699, and rs3160). Because 
rs27699 was in high LD with rs26865 (r2 = 0.911), we only 
chose rs26865. Finally, we selected one SNP in the promoter 
region of mLST8 (rs26865 G>A) and one SNP in the 3′UTR 
of mLST8 (rs3160 C>T) for genotyping.
In the present study, we could not include any SNPs 
in exons for genotyping because no nonsynonymous SNPs 
met the selection criteria with MAF ≥ 5% in Chinese Han, 
Beijing. Genomic DNA was isolated from blood samples, and 
the TaqMan assay was performed for genotyping, as described 
previously.15
Statistical Methods
The χ2 test was used to assess differences in the fre-
quency distributions of the selected demographic variables, 
risk factors, and genotype of the selected SNPs between the 
cases and controls. Univariate and multivariate logistic regres-
sion analyses were performed to calculate crude and adjusted 
ORs and their 95% confidence intervals (CIs) for ESCC risk, 
which were also stratified by the subgroups of age, sex, BMI, 
and smoking and drinking status. The Hardy–Weinberg equi-
librium for genotype distribution in controls was tested by a 
goodness-of-fit χ2 test.
To account for chance associations from multiple com-
parisons, we used the false-positive report probability (FPRP) 
to assess the false-positive association findings. We calculated 
FPRP with prior probabilities of 0.0001, 0.001, 0.01, 0.1, and 
0.25. Results with an FPRP value less than 0.20 were consid-
ered a noteworthy association.16 All tests were two-sided, and 
a p < 0.05 was considered statistically significant. All statisti-
cal analyses were performed with SAS software (version 9.1; 
SAS Institute, Cary, NC).
The possible high-order gene–gene or gene–environment 
interactions in the association with ESCC risk were identified 
by using the multiple dimension reduction (MDR) software 
(V2.0 beta 8.2).17 We used 100-fold cross-validation and 
1000-fold permutation testing under the null hypothesis of 
no association, and the best candidate interaction model was 
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selected as the one with the minimum average prediction error 
and the maximum cross-validation consistency (CVC).
RESULTS
Characteristics of the Study Population
There were no statistically significant differences in the 
distributions of age and sex between the cases and controls. 
However, the cases were more likely to be smokers (61.55% 
versus 54.02%; p = 0.0003) and drinkers (44.44% versus 
32.63%; p < 0.0001) as well as having BMI < 25.0 (63.68% 
versus 43.94%; p < 0.0001) than the controls (Table 1). 
Therefore, these variables were further adjusted for in later 
multivariate analyses.
Association between Eight 
Selected SNPs and ESCC Risk
All the observed genotype frequencies for the eight 
selected SNPs agreed with the Hardy–Weinberg equilib-
rium in the controls, and all the SNP calling rates were more 
than 99.00%. In the single-locus analyses, we found that sig-
nificantly increased ESCC risk was associated with mTOR 
rs1883965 A variant genotypes (adjusted OR = 1.27, 95% CI = 
1.01–1.60 for GA versus GG; adjusted OR = 1.26, 95% CI = 
1.01–1.58 for GA/AA versus GG) and RPTOR rs12602885 A 
variant genotypes (adjusted OR = 0.68, 95% CI = 0.47–0.98 
for AA versus GG). However, these risk associations were not 
observed for other individual SNPs (Table 2).
In the combined analysis of eight SNPs in mTORC1, we 
categorized all putative risk (OR > 1.0) genotypes from each 
SNP into a new variable according to the number of risk geno-
types (for the protective genotype, OR < 1.0, we reversed the 
reference group). As a result, we found that individuals with 
two or more unfavorable genotypes exhibited increased risk 
for ESCC (adjusted OR = 1.35, 95% CI = 1.20–1.62), com-
pared with those with less than two unfavorable genotypes. 
Furthermore, such a cumulative effect on risk was risk-geno-
type dose-dependent, as evidenced by a significantly increased 
risk of ESCC with an increasing number of observed risk gen-
otypes (adjusted OR = 2.40, 95% CI = 1.19–4.83 for two risk 
genotypes; adjusted OR = 2.45, 95% CI = 1.22–4.94 for three 
risk genotypes; adjusted OR = 2.82, 95% CI = 1.36–5.84 for 
four risk genotypes; p
trend
 = 0.004; Table 2). In addition, we dis-
covered that a combination of SNPs in all genes under inves-
tigation produced a higher level of risk compared with two 
SNPs in the same gene (Supplementary Table 1, Supplemental 
Digital Content 1, http://links.lww.com/JTO/A403).
Stratification Analysis
We further estimated the combined effect of those 
unfavorable genotypes on ESCC risk stratified by selected 
variables. As shown in Table 3, the increased risk of ESCC 
associated with two or more unfavorable genotypes was 
more pronounced among older subjects (adjusted OR= 1.66, 
95% CI = 1.29–2.15), males (adjusted OR = 1.41, 95% CI = 
1.15–1.74), ever-smokers (adjusted OR = 1.55, 95% CI = 
1.21–1.98), never-drinkers (adjusted OR = 1.47, 95% CI = 
1.16–1.86) and subjects with BMI < 25.0 (adjusted OR = 1.41, 
95% CI = 1.10–1.80), compared with those with less than two 
unfavorable genotypes. However, further homogeneity tests 
showed that there were no significant differences (p > 0.05) 
among all strata except for older subjects (p for homogeneity = 
0.026). In addition, there was no statistical evidence of gene–
environment interactions between the variant genotypes and 
these variables on ESCC risk.
Association of High-Order Interactions 
with ESCC Risk by MDR Analysis
In the MDR analysis, we found that rs1883965 was the 
best one-factor model with a maximum CVC of 98 of 100 and 
a minimum lowest prediction error of 48.4% among all stud-
ied SNPs (p = 0.0479 for the prediction error). More interest-
ingly, the eight-factor model including the combination of all 
studied SNPs had a minimum prediction error of 33.2% and 
a maximum CVC of 100 of 100, and the prediction error was 
statistically significant (p < 0.0001), which was showed to be 
the best model to predict ESCC risk for this study population 
(Table 4).
FPRP Values for All Significant Associations
With the assumption of a moderate prior probability of 
0.1 and the observed ORs, the FPRP values were 0.174, 0.150, 




Variables Controls, No. (%) Cases, No. (%) pa
All subjects 1131 (100%) 1126 (100%)
Age, yr (mean±SD)b 60.77 ± 10.24 60.40 ± 8.30 0.125
 ≤50 156 (13.79) 138 (12.26)
 >50, ≤60 405 (35.81) 422 (37.48)
 >60, ≤70 401 (35.46) 429 (38.10)
 >70 169 (14.94) 137 (12.17)
Sex 0.078
 Males 879 (77.72) 909 (80.37)
 Females 252 (22.28) 217 (19.27)
Smoking status 0.0003
 Yes 611 (54.02) 693 (61.55)
 No 520 (45.98) 433 (38.45)
Drinking status <0.0001
 Yes 369 (32.63) 501 (44.44)
 No 762 (67.37) 625 (55.56)
Pack-years <0.0001
 0 520 (45.98) 429 (38.10)
 ≤16 (mean) 245 (21.66) 152 (13.50)
 >16 (mean) 366 (32.36) 545 (48.40)
Body mass index <0.0001
 <25.0 497 (43.94) 717 (63.68)
 ≥25.0 634 (56.06) 409 (36.32)
a Two-sided χ2 test for distributions between cases and controls.
b Data are mean±SD and p value from Student’s t test.
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TABLE 2.  Genotype Frequencies of the mTOR, mLST8, RPTOR Polymorphisms and their Association with Risk of Esophageal 
Squamous Cell Carcinoma
Variants Casesa, No. (%) Controlsa, No. (%) pb Crude OR (95% CI) pc Adjusted OR (95% CI)b pd
mTOR rs1883965
 GG 908 (80.85) 940 (83.85) 0.148e 1.00 1.00
 GA 209 (18.62) 174 (15.53) 1.24 (1.00–1.55) 0.053 1.27 (1.01–1.60) 0.042
 AA 6 (0.53) 7 (0.62) 0.89 (0.30–2.65) 0.831 1.02 (0.33–3.16) 0.971
 GA/AA 215 (19.15) 181 (16.15) 0.062f 1.23 (0.99–1.53) 0.063 1.26 (1.01–1.58) 0.045
 GG/GA 1117 (99.47) 1114 (99.38) 1.00 1.00
 AA 6 (0.53) 7 (0.62) 0.778g 0.86 (0.29–2.55) 0.779 0.98 (0.32–3.03) 0.973
mTOR rs2536
 TT 951 (84.68) 957 (85.37) 0.898e 1.00 1.00
 TC 165 (14.69) 157 (14.01) 1.06 (0.84–1.34) 0.642 1.12 (0.88–1.43) 0.365
 CC 7 (0.62) 7 (0.62) 1.01 (0.35–2.88) 0.991 1.21 (0.41–3.57) 0.736
 TC/CC 172 (15.32) 164 (14.63) 0.649f 1.06 (0.84–1.33) 0.649 1.12 (0.88–1.43) 0.343
 TC/TT 1116 (99.38) 1114 (99.38) 1.00 1.00
 CC 7 (0.62) 7 (0.62) 0.997g 1.00 (0.35–2.86) 1.000 1.19 (0.40–3.51) 0.759
mLST8 rs3160
 CC 301 (26.83) 285 (25.42) 0.711e 1.00 1.00
 CT 567 (50.53) 571 (50.94) 0.94 (0.77–1.15) 0.545 0.93 (0.75–1.14) 0.462
 TT 254 (22.64) 265 (23.64) 0.91 (0.72–1.15) 0.421 0.88 (0.69–1.12) 0.289
 CT/TT 821 (73.17) 836 (74.58) 0.449f 0.93 (0.77–1.12) 0.450 0.91 (0.75–1.11) 0.341
 CT/CC 868 (77.36) 856 (76.36) 1.00 1.00
 TT 254 (22.64) 265 (23.64) 0.574g 0.95 (0.78–1.15) 0.574 0.92 (0.75–1.13) 0.443
mLST8 rs26865
 GG 399 (35.56) 369 (32.92) 0.206e 1.00 1.00
 GA 540 (48.13) 541 (48.26) 0.92 (0.77–1.11) 0.397 0.90 (0.75–1.10) 0.302
 AA 183 (16.31) 211 (18.82) 0.80 (0.63–1.02) 0.076 0.81 (0.63–1.04) 0.092
 GA/AA 723 (64.44) 752 (67.08) 0.187f 0.89 (0.75–1.06) 0.187 0.88 (0.73–1.05) 0.152
 GA/GG 939 (83.69) 910 (81.18) 1.00 1.00
 AA 183 (16.31) 211 (18.82) 0.118g 0.84 (0.68–1.05) 0.119 0.85 (0.68–1.07) 0.170
RPTOR rs3751934
 CC 409 (36.55) 430 (38.43) 0.191e 1.00 1.00
 CA 529 (47.27) 538 (48.08) 1.03 (0.86–1.24) 0.719 1.07 (0.89–1.30) 0.461
 AA 181 (16.18) 151 (13.49) 1.26 (0.98–1.63) 0.075 1.27 (0.97–1.65) 0.081
 CA/AA 710 (63.45) 689 (61.57) 0.359f 1.08 (0.91–1.29) 0.359 1.12 (0.93–1.33) 0.226
 CA/CC 938 (83.82) 968 (86.51) 1.00 1.00
 AA 181 (16.18) 151 (13.49) 0.074g 1.24 (0.98–1.56) 0.075 1.22 (0.95–1.55) 0.113
RPTOR rs1062935
 TT 307 (27.44) 318 (28.42) 0.874e 1.00 1.00
 TC 564 (50.40) 557 (49.78) 1.05 (0.86–1.28) 0.633 1.08 (0.89–1.33) 0.434
 CC 248 (22.16) 244 (21.81) 1.05 (0.83–1.33) 0.670 1.07 (0.84–1.37) 0.592
 TC/CC 812 (72.56) 801 (71.58) 0.604f 1.05 (0.87–1.26) 0.604 1.08 (0.89–1.31) 0.432
 TC/TT 871 (77.84) 875 (78.19) 1.00 1.00
 CC 248 (22.16) 244 (21.81) 0.838g 1.02 (0.84–1.25) 0.838 1.02 (0.83–1.25) 0.885
RPTOR rs3751932
 TT 840 (75.07) 846 (75.60) 0.144e 1.00 1.00
 TC 250 (22.34) 257 (22.97) 0.98 (0.80–1.20) 0.840 0.99 (0.81–1.22) 0.938
 CC 29 (2.59) 16 (1.43) 1.83 (0.98–3.39) 0.056 1.83 (0.97–3.47) 0.064
 TC/CC 279 (24.93) 273 (24.40) 0.449f 1.03 (0.85–1.25) 0.769 1.04 (0.85–1.27) 0.691
 TC/TT 1090 (97.41) 1103 (98.57) 1.00 1.00
 CC 29 (2.59) 16 (1.43) 0.050g 1.83 (0.99–3.40) 0.054 1.83 (0.97–3.47) 0.062
(Continued)
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to 6 combined risk genotypes with an increased risk of ESCC in 
all subjects and in subgroups of older subjects. The FPRPs for 
all of the above-mentioned significant associations were below 
the threshold of 0.20, suggesting that these associations were 
noteworthy findings as presented in the current study (Table 5).
DISCUSSION
In the present study, we found that mTOR rs1883965 
A variant genotypes were individually associated with an 
increased ESCC risk in the Eastern Chinese population. 
When all unfavorable genotypes were combined, risk of 
ESCC increased as the number of at-risk genotypes increased, 
suggesting that these eight SNPs may collectively contribute 
to risk of ESCC. Furthermore, results from the MDR analy-
sis also consistently identified mTOR rs1883965 as the main 
single susceptibility locus and the combinations of all studies 
SNPs contributed to ESCC risk. These findings seem to be 
biologically plausible.
It is known that the mTOR protein is involved in a 
complex signaling network of controlling cell growth, pro-
liferation, cell cycle, and autophagy,11 and the knockdown of 
mTOR in mice is embryonically lethal.18 In addition, RPTOR 
interacts with mTOR to make the phosphorylation reaction 
of S6K1 and 4EBP1 possible, the two well-characterized 
mTORC1 effectors.19 Similar to the knockout of mTOR, the 
knockout of RPTOR is also early embryonically lethal,20 
which underscores the biological importance of this gene. A 
previous study found that the knockdown of mLST8 in cells 
may suppress the phosphorylation of S6K1 and 4EBP1.19
To date, only two reported studies have investigated the 
association between mTOR polymorphisms and risk of can-
cers. One earlier U.S. study of 1574 colon cancer cases and 
1940 healthy controls found that one tagSNP rs1057079 was 
associated with a significantly increased colon cancer risk.21 
The later study conducted in Chinese children with 417 acute 
lymphoblastic leukemia cases and 554 controls showed a pro-
tective effect of rs2536 on risk of acute lymphoblastic leu-
kemia,14 which is not in agreement with our findings that no 
association was observed for the rs2536 variant with ESCC 
risk. Recently, an American study of 803 bladder cancer cases 
and 803 controls showed that RPTOR gene polymorphisms, 
including rs1062935, were associated with an increased 
cancer risk,22 which is not consistent with our null result for 
rs1062935. Taken together, the inconsistent results between 
the present study and those studies with similar SNPs but 
different cancers by others may be due to different genetic 
backgrounds or etiologies of various cancers. For example, 
the mTOR rs2536 C allele frequency of the controls in the 
above-mentioned Chinese study and ours was similar (0.098 
versus 0.076), suggesting that there was no methodological 
TABLE 2. (Continued)
Variants Casesa, No. (%) Controlsa, No. (%) pb Crude OR (95% CI) pc Adjusted OR (95% CI)b pd
RPTOR rs12602885
 GG 629 (56.21) 607 (54.24) 0.184e 1.00 1.00
 GA 433 (38.70) 435 (38.87) 0.96 (0.81–1.14) 0.650 0.92 (0.77–1.10) 0.347
 AA 57 (5.09) 77 (6.88) 0.71 (0.50–1.02) 0.067 0.68 (0.47–0.98) 0.040
 GA/AA 490 (43.79) 512 (45.76) 0.350f 0.92 (0.78–1.09) 0.350 0.88 (0.74–1.05) 0.150
 GA/GG 1062 (94.91) 1042 (93.12) 1.00 1.00
 AA 57 (5.09) 77 (6.88) 0.075g 0.73 (0.51–1.03) 0.076 0.70 (0.49–1.01) 0.056
No. of at-risk genotypesh
 0 13 (1.16) 27 (2.41) 0.047 1.00 1.00
 1 324 (28.98) 376 (33.60) 1.79 (0.91–3.53) 0.093 1.91 (0.95–3.82) 0.070
 2 309 (27.64) 291 (26.01) 2.21 (1.12–4.36) 0.023 2.40 (1.19–4.83) 0.014
 3 286 (25.58) 263 (23.50) 2.26 (1.14–4.47) 0.019 2.45 (1.22–4.94) 0.012
 4 137 (12.25) 114 (10.19) 2.50 (1.23–5.06) 0.011 2.82 (1.36–5.84) 0.005
 5 43 (3.85) 40 (3.57) 2.23 (1.01–4.92) 0.046 2.42 (1.07–5.43) 0.033
 6 6 (0.54) 8 (0.71) 1.56 (0.45–5.43) 0.487 1.79 (0.49–6.56) 0.383
 Trend 0.008 0.004
Dichotomized groups
 0–1 337 (30.14) 403 (36.01) 0.003 1.00 1.00
 2–6 781 (69.86) 716 (63.99) 1.30 (1.09–1.56) 0.003 1.35 (1.20–1.62) 0.002
a The numbers of each single nucleotide polymorphism were less than the total number of subjects because some genotyping data were unavailable.
b Two sides χ2 test for genotype distributions between cases and controls.
c Unadjusted for age, sex, BMI, smoking status, and drinking status in logistic regression models.
d Adjusted for age, sex, BMI, smoking status, and drinking status in logistic regression models.
e For additive genetic models.
f For dominant genetic models.
g For recessive genetic models.
h The risk genotypes used for the calculation were mTOR rs1883965 GA/AA + rs2536 TC/CC, mLST8 rs3160 CC + rs26865 GG, RPTOR rs3751934 AA + rs1062935 CC + 
rs3751932 CC + rs12602885 GA+GG.
CI, confidence interval; BMI, body mass index.
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bias in the genotyping method. Further validations in addi-
tional larger studies of different cancer types either in addi-
tional group of homogenous ethnicity or in more ethnically 
diverse groups are warranted.
The present study, for the first time, found that SNP 
rs1883965 located in the intron-1 region of mTOR was asso-
ciated with increased ESCC risk. Several studies have dis-
covered that some disease-associated functional intronic 
variants may alter mRNA levels of genes by affecting the 
transcriptional efficiency, RNA elongation, or splicing.23–25 
For rs1883965, TRANSFA (http://www.gene-regulation.
com) has predicted that it may affect the transcription factor 
binding site activity. Therefore, we speculated that it may be 
a causal SNP or in LD with either other functional polymor-
phisms, thereby altering the function of mTOR or with SNPs 
of an adjacent susceptibility gene. In fact, further LD analysis 
using the SNPinfo database found that rs1883965 was in high 
LD with a synonymous SNP rs1064261 (r2 = 0.864), which 
was predicted to have an effect on splicing. It should be noted 
that the results derived from single SNP analysis tend to have 
a high false discovery rate, because multiple hypotheses are 
tested simultaneously and that the probability of type I error 
rates inflates with the increasing number of tests. Indeed, 
in the present study, greater FPRP values observed for the 
significant associations of rs1883965 variants with ESCC 
risk suggested a possible false-positive finding. However, all 
methods of testing multiple comparisons are very conserva-
tive when exploring candidate genes with a prior hypothesis. 
In any rate, additional large studies are required to replicate 
our findings.
We noticed that effect of the combined unfavor-
able genotypes on ESCC risk was more pronounced among 
older subjects. It is likely that older subjects may have been 
exposed environmental carcinogens for a longer time, which 
possibly led to more DNA damage that may have interacted 
with genetic variations in initiating carcinogenesis. However, 
we observed neither associations for other subgroups nor 
any statistical evidence for gene–environment interactions 
between the variant genotypes and these variables on risk of 
ESCC. The possible reason may be that this subgroup finding 
often suffers from reduced statistical power or simply due to 




Best Model Cross-Validation Avg. Prediction Error pa
1 98/100 0.484 0.0479
2, 3 98/100 0.466 0.0002
2, 3, 4 100/100 0.448 <0.0001
2, 3, 4, 5 75/100 0.436 <0.0001
1, 2, 3, 4, 6 100/100 0.414 <0.0001
1, 2, 3, 4, 6, 7 100/100 0.389 <0.0001
1, 2, 3, 4, 6, 7, 8 86/100 0.362 <0.0001
1, 2, 3, 4, 5, 6, 7, 8b 100/100 0.332 <0.0001
a p value for 1,000-fold permutation test.
b The best model was selected as the one with the minimum average prediction error 
and maximum cross-validation. In this study, the best interaction model is indicated in 
boldface.
Labels: 1: rs1883965, 2: rs3751934, 3: rs1062935, 4: rs26865, 5: rs2536, 6: rs12602885, 
7: rs3160, and 8: rs3751932.
TABLE 3.  Stratification Analysis for Associations between Combined Risk Genotypes of mTOR, mLST8, and RPTOR 
Polymorphisms and Esophageal Squamous Cell Carcinoma Risk
Variables
Combined Effect of Risk Genotypes  
(Cases/Controls, n, %)
Crude OR  
(95% CI) p
Adjusted ORa 
(95% CI) pa pb pc
0–1 At-Risk Genotype 2–6 At-Risk Genotype
Age, yr (median)
 ≤60 173/180 (31.06/32.37) 384/376 (68.94/67.63) 1.06 (0.83–1.37) 0.638 1.08 (0.83–1.41) 0.587 0.026 0.235
 >60 164/223 (29.23/39.61) 397/340 (70.77/60.39) 1.59 (1.24–2.04) 0.000 1.66 (1.29–2.15) 0.000
Sex
 Males 268/319 (29.65/36.67) 636/551 (70.35/63.33) 1.37 (1.13–1.68) 0.002 1.41 (1.15–1.74) 0.001 0.261 0.286
 Females 69/84 (32.24/33.73) 145/165 (67.76/66.27) 1.07 (0.73–1.58) 0.734 1.04 (0.69–1.57) 0.861
Smoking status
 Never 136/172 (31.63/33.46) 294/342 (68.37/66.54) 1.09 (0.83–1.43) 0.550 1.11 (0.84–1.47) 0.472 0.081 0.075
 Ever 201/231 (29.22/38.18) 487/374 (70.78/61.82) 1.50 (1.19–1.89) 0.001 1.55 (1.21–1.98) 0.001
Drinking status
 Never 180/279 (28.99/37.00) 441/475 (71.01/63.00) 1.44 (1.15–1.81) 0.002 1.47 (1.16–1.86) 0.001 0.183 0.230
 Ever 156/124 (31.45/33.97) 340/241 (68.55/66.03) 1.12 (0.84–1.50) 0.435 1.12 (0.83–1.52) 0.452
BMI
 <25.0 219/189 (30.72/38.34) 494/304 (69.28/61.66) 1.40 (1.10–1.79) 0.006 1.41 (1.10–1.80) 0.006 0.442 0.358
 ≥25.0 118/214 (29.14/34.19) 287/412 (70.86/65.81) 1.26 (0.96–1.66) 0.087 1.25 (0.95–1.64) 0.108
a Obtained in logistic regression models with adjustment for age, sex, BMI, smoking status, and drinking status.
b p for homogeneity test using the χ2-based Q test.
c Test for multiplicative interaction obtained from logistic regression models with adjustment for age, sex, BMI, smoking status, and drinking status.
CI, confidence interval; BMI, body mass index.
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Some significant findings of the present study suggested 
some complex gene–gene interactions, which were consis-
tently identified through different analytic approaches. In the 
logistic regression model, a locus dose–response was found 
for the increased ESCC risk with the increasing number of 
risk or unfavorable genotypes of all studied SNPs. In the MDR 
analysis, eight-factor model, including the combination of all 
studied SNPs, is the best model to predict ESCC risk in this 
study population. These results suggest that all studied SNPs 
may have a joint effect on risk of ESCC, although the evidence 
of true interactions was weak and the mechanisms underlying 
these high interactions remain to be elucidated. Given their 
integration of functions of the multiprotein complex consist-
ing of mTOR, RPTOR, and mLST8 in the mTORC1 pathway, 
it is biologically plausible for these potentially functional 
polymorphisms to have a synergistic effect that was detected 
in this study.
In summary, the present study investigated the asso-
ciations between mTORC1 polymorphisms and ESCC risk 
with a relatively large sample size. One strength is that we 
used diverse approaches to analyze the data, including logis-
tic regression and MDR, for accessing possible interactions. 
However, there are some inherited limitations. First, as a hos-
pital-based case–control study, this study may be subject to 
inherent biases for selection of the nonrepresentative subjects 
and retrospective collection of exposure data. Second, the 
selection of SNPs was based on prior knowledge of potentially 
functional SNPs instead of tagging SNPs, which may miss 
some important variations within the genes. Finally, because 
the MAF of some SNPs in the present study was low, we had 
limited statistical power to detect significant associations in 
some subgroups, let alone the power to assess gene–environ-
ment interactions adequately. Therefore, additional larger, 
well-designed, and population-based studies are warranted to 
confirm our findings.
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